Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Total Non-Current Liabilities (2020 - 2025)

Puma Biotechnology (PBYI) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $86.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities fell 29.01% year-over-year to $86.0 million, compared with a TTM value of $86.0 million through Dec 2025, down 29.01%, and an annual FY2025 reading of $86.0 million, down 29.01% over the prior year.
  • Total Non-Current Liabilities was $86.0 million for Q4 2025 at Puma Biotechnology, down from $87.6 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $242.0 million in Q1 2021 and bottomed at $86.0 million in Q4 2025.
  • Average Total Non-Current Liabilities over 5 years is $165.5 million, with a median of $167.4 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities increased 0.07% in 2024, then crashed 42.32% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $229.0 million in 2021, then fell by 12.48% to $200.4 million in 2022, then dropped by 11.7% to $177.0 million in 2023, then plummeted by 31.58% to $121.1 million in 2024, then dropped by 29.01% to $86.0 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for PBYI at $86.0 million in Q4 2025, $87.6 million in Q3 2025, and $90.2 million in Q2 2025.